Wedbush Has Pessimistic Outlook of argenex Q3 Earnings

Key Points

• Wedbush has downgraded its Q3 2025 earnings per share estimate for argenex from $6.72 to $5.60, while maintaining an "Outperform" rating and a price target of $800.00.
• For the current fiscal year, the consensus earnings estimate for argenex is projected at $3.13 per share, with long-term earnings expected to significantly increase, reaching $53.13 per share by FY2028.
• Despite the downgraded earnings estimates, argenex's recent quarter reported earnings of $3.74 per share, beating analysts' expectations and reflecting strong revenue growth of $866.79 million.

argenex SE (NASDAQ:ARGX - Free Report) - Equities researchers at Wedbush reduced their Q3 2025 earnings per share estimates for shares of argenex in a research note issued on Monday, August 25th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of $5.60 per share for the quarter, down from their previous forecast of $6.72. Wedbush has a "Outperform" rating and a $800.00 price objective on the stock. The consensus estimate for argenex's current full-year earnings is $3.13 per share. Wedbush also issued estimates for argenex's Q4 2025 earnings at $6.24 EPS, Q1 2026 earnings at $6.78 EPS, Q2 2026 earnings at $6.23 EPS, Q3 2026 earnings at $6.75 EPS, Q4 2026 earnings at $7.30 EPS, FY2026 earnings at $27.07 EPS, FY2027 earnings at $36.64 EPS and FY2028 earnings at $53.13 EPS.

argenex (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The company reported $3.74 EPS for the quarter, beating the consensus estimate of $2.84 by $0.90. The business had revenue of $866.79 million during the quarter, compared to analysts' expectations of $776.82 million. argenex had a return on equity of 21.06% and a net margin of 40.98%.

ARGX has been the subject of several other research reports. Oppenheimer boosted their price target on argenex from $704.00 to $708.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Baird R W raised argenex from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, May 13th. Robert W. Baird raised argenex from a "neutral" rating to an "outperform" rating and set a $680.00 price target for the company in a research note on Tuesday, May 13th. Morgan Stanley boosted their price target on argenex from $700.00 to $766.00 and gave the company an "overweight" rating in a research note on Friday, August 1st. Finally, Royal Bank Of Canada began coverage on argenex in a research note on Monday, August 25th. They issued an "outperform" rating and a $850.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating and twenty have issued a Buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $766.50.

argenex Stock Performance

Shares of NASDAQ ARGX traded up $8.13 during trading hours on Wednesday, hitting $712.20. The stock had a trading volume of 353,562 shares, compared to its average volume of 393,011. The company has a market capitalization of $43.59 billion, a P/E ratio of 36.52, a P/E/G ratio of 0.81 and a beta of 0.39. The firm's 50-day moving average price is $611.18 and its two-hundred day moving average price is $599.48. argenex has a 52 week low of $510.05 and a 52 week high of $716.62.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Rakuten Securities Inc. lifted its holdings in shares of argenex by 56.4% during the first quarter. Rakuten Securities Inc. now owns 61 shares of the company's stock worth $36,000 after buying an additional 22 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of argenex during the fourth quarter worth approximately $38,000. WPG Advisers LLC acquired a new position in shares of argenex during the first quarter worth approximately $37,000. Golden State Wealth Management LLC acquired a new position in shares of argenex during the first quarter worth approximately $44,000. Finally, Brooklyn Investment Group lifted its holdings in shares of argenex by 102.7% during the first quarter. Brooklyn Investment Group now owns 75 shares of the company's stock worth $44,000 after buying an additional 38 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.